Neelyx Labs announces immediate capacity for rapid monkeypox PCR testing
July 11, 2022Independent diagnostics laboratory can process 8,000 CDC-compliant tests per day to support consumer and healthcare demand
CHICAGO–(BUSINESS WIRE)–Amid rising concerns about a lack of testing to stop the spread of the monkeypox virus, Neelyx Labs, an independent diagnostics firm based in the Chicago area, announced they are now processing monkeypox PCR tests, with a capacity of 8,000 tests per day. Neelyx also delivers stat tests with a 1-hour turnaround using the XDiveTM ultrafast, real-time PCR instrument.
Hospitals, clinics, public health entities, and commercial laboratories can contact Neelyx Labs at (630) 214-3800 or [email protected].
Neelyx Labs was established in 2020 to provide accurate, timely diagnosis of COVID-19 and its variants with RT-PCR testing and clinical sequencing. Since the emergence of monkeypox in the United States, Neelyx Labs has released a CDC-compliant PCR test for the virus that supports testing of dry swabs, swabs in transport media (wet swabs), lesions, and saliva.
“We have high capacity that was proven during COVID, and we’ve duplicated those logistics for monkeypox testing,” said Shyam Saladi, CEO and lead scientist at Neelyx Labs. “Healthcare facilities and public health departments need flexibility and capacity to process thousands of specimens in aggregate or to focus on smaller subsets of high-priority cases. We support this with fast turnaround of PCR test results within 20 minutes through existing EMR portals.”
Neelyx Labs partners with OnsiteGene Inc., a San Diego-based biotechnology company supported by the National Institutes of Health’s Rapid Acceleration of Diagnosis (RADx) program, to deploy the XDive PCR machine. XDive can complete 40 cycles of real-time PCR testing in as little as five minutes, while delivering fully automated sample-to-answer qPCR testing, nested PCR, or PCR with automated pre-amplification.
“XDive pushes the boundary of qPCR testing with order-of-magnitude improvements in run time and limit of detection,” said Thomas Gong, president of OnsiteGene. “This is a breakthrough for many infectious disease applications that require fast turnaround and extreme sensitivity.”
Neelyx Labs follows all state and federal health guidelines and provides quick communication to public health officials to track and mitigate the spread of pathogens. For more information, visit www.neelyx.com.
About Neelyx Labs
Neelyx Labs is a next-generation, independent, diagnostics laboratory developing advanced rapid disease detection strategies for healthcare organizations, public health entities, commercial laboratories, and life sciences companies. The company has developed innovative clinical diagnostics using PCR and NGS technology, including one of the first COVID-19 variant tests, the fastest RT-PCR test for COVID-19, and innovative antigen tests for COVID-19. To learn more, visit www.neelyx.com.
About OnsiteGene
Based in San Diego, OnsiteGene, Inc. is a subsidiary of Star Array Pte Ltd., a bioengineering company that develops nucleic acid testing instruments, consumables, reagents, and test kits. OnsiteGene’s vision is to make highly affordable automated nucleic acid testing available anywhere at any time for both laboratory testing and POCT applications. To learn more, visit www.onsitegene.com.
Contacts
Barbara Tabor, APR
651.230.9192 / [email protected]